Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 Jun 16;8(2):E413–E418. doi: 10.1007/BF02854914

Mechanisms of methamphetamine-induced dopaminergic neurotoxicity

Evan L Riddle 1, Annette E Fleckenstein 1, Glen R Hanson 1,✉
PMCID: PMC3231576  PMID: 16808044

Abstract

Methamphetamine (METH) is a powerful stimulant of abuse with potent addictive and neurotoxic properties. More than 2.5 decades ago, METH-induced damage to dopaminergic neurons was described. Since then, numerous advancements have been made in the search for the underlying mechanisms whereby METH causes these persistent dopaminergic deficits. Although our understanding of these mechanisms remains incomplete, combinations of various complex processes have been described around a central theme involving reactive species, such as reactive oxygen and/or nitrogen species (ROS and RNS, respectively). For example, METH-induced hyperthermia, aberrant dopamine (DA), or glutamate transmission; or mitochondrial disruption leads to the generation of reactive species with neurotoxic consequences. This review will describe the current understanding of how high-dose METH administration leads to the production of these toxic reactive species and consequent permanent dopaminergic deficits.

Keywords: basal ganglia, dopamine, dopamine transporter, methamphetamine, neurotoxicity, vesicular monoamine transporter-2

Full Text

The Full Text of this article is available as a PDF (194.8 KB).

References

  • 1.Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2:699–703. doi: 10.1038/nm0696-699. [DOI] [PubMed] [Google Scholar]
  • 2.Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of metham phetamine on tryptophan hydroxylase and tyrosine hydroxylase in rat brain. J Pharmacol Exp Ther. 1980;214:257–262. [PubMed] [Google Scholar]
  • 3.Hotchkiss AJ, Morgan ME, Gibb JW. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci. 1979;25:1373–1378. doi: 10.1016/0024-3205(79)90414-4. [DOI] [PubMed] [Google Scholar]
  • 4.Woolverton WL, Ricaurte GA, Forno L, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 1989;486:73–78. doi: 10.1016/0006-8993(89)91279-1. [DOI] [PubMed] [Google Scholar]
  • 5.Cubells JF, Rayport S, Rajendran G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 1994;14:2260–2271. doi: 10.1523/JNEUROSCI.14-04-02260.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol. 2003;479:283–289. doi: 10.1016/j.ejphar.2003.08.077. [DOI] [PubMed] [Google Scholar]
  • 7.Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci. 1999;19:2424–2431. doi: 10.1523/JNEUROSCI.19-07-02424.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol. 2002;449:71–74. doi: 10.1016/S0014-2999(02)01985-4. [DOI] [PubMed] [Google Scholar]
  • 9.Rau KS, Birdsall E, Hanson JE, et al. Buproprion increases striatal vesicular monoamine transport. Neuropharmacology. 2005;49:820–830. doi: 10.1016/j.neuropharm.2005.05.004. [DOI] [PubMed] [Google Scholar]
  • 10.Truong JG, Wilkins DG, Baudys J, et al. Age-dependent metham phetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther. 2005;314:1087–1092. doi: 10.1124/jpet.105.085951. [DOI] [PubMed] [Google Scholar]
  • 11.Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther. 2003;304:1181–1187. doi: 10.1124/jpet.102.045005. [DOI] [PubMed] [Google Scholar]
  • 12.Brown JM, Riddle EL, Sandoval V, et al. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther. 2002;302:497–501. doi: 10.1124/jpet.302.2.497. [DOI] [PubMed] [Google Scholar]
  • 13.Truong JG, Newman AH, Hanson GR, Fleckenstein AE. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Eur J Pharmacol. 2004;504:27–32. doi: 10.1016/j.ejphar.2004.09.049. [DOI] [PubMed] [Google Scholar]
  • 14.Kuczenski R, Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci. 1989;9:2051–2065. doi: 10.1523/JNEUROSCI.09-06-02051.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995;15:4102–4108. doi: 10.1523/JNEUROSCI.15-05-04102.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther. 1997;282:834–838. [PubMed] [Google Scholar]
  • 17.Cervinski MA, Foster JD, Vaughan RA. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J Biol Chem. 2005;280:40442–40449. doi: 10.1074/jbc.M501969200. [DOI] [PubMed] [Google Scholar]
  • 18.Saunders C, Ferrer JV, Shi L, et al. Amphetamine-induced loss of human dopamine transporter activity; an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850–6855. doi: 10.1073/pnas.110035297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kokoshka JM, Vaughan RA, Hanson GR, Fleckenstein AE. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol. 1998;361:269–275. doi: 10.1016/S0014-2999(98)00741-9. [DOI] [PubMed] [Google Scholar]
  • 20.Baucum AJ, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci. 2004;24:3436–3443. doi: 10.1523/JNEUROSCI.0387-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Giovanni A, Liang LP, Hastings TG, Zigmond MJ. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem. 1995;64:1819–1825. doi: 10.1046/j.1471-4159.1995.64041819.x. [DOI] [PubMed] [Google Scholar]
  • 22.Fleckenstein AE, Wilkins DG, Gibb JW, Hanson GR. Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther. 1997;283:281–285. [PubMed] [Google Scholar]
  • 23.Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 1998;287:107–114. [PubMed] [Google Scholar]
  • 24.LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. 1999;19:1484–1491. doi: 10.1523/JNEUROSCI.19-04-01484.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wagner GC, Carelli RM, Jarvis MF. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Pathol Pharmacol. 1985;47:221–228. [PubMed] [Google Scholar]
  • 26.De Vito MJ, Wagner GC. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 1989;28:1145–1150. doi: 10.1016/0028-3908(89)90130-5. [DOI] [PubMed] [Google Scholar]
  • 27.Colado MI, Green AR. The spin trap reagent alpha-phenyl-N-tertbutyl nitrone prevents ‘ecstasy’-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol. 1995;280:343–346. doi: 10.1016/0014-2999(95)00298-Y. [DOI] [PubMed] [Google Scholar]
  • 28.Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem. 1994;62:380–383. doi: 10.1046/j.1471-4159.1994.62010380.x. [DOI] [PubMed] [Google Scholar]
  • 29.Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998;32:117–131. doi: 10.1016/S0197-0186(97)00031-4. [DOI] [PubMed] [Google Scholar]
  • 30.Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004;311:1–7. doi: 10.1124/jpet.104.070961. [DOI] [PubMed] [Google Scholar]
  • 31.Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett. 2004;367:349–354. doi: 10.1016/j.neulet.2004.06.065. [DOI] [PubMed] [Google Scholar]
  • 32.Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol. 2005;193:279–290. doi: 10.1016/j.expneurol.2005.01.013. [DOI] [PubMed] [Google Scholar]
  • 33.Thomas DM, Kuhn DM. Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem. 2005;92:790–797. doi: 10.1111/j.1471-4159.2004.02906.x. [DOI] [PubMed] [Google Scholar]
  • 34.Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978;14:633–643. [PubMed] [Google Scholar]
  • 35.Chiueh CC, Miyake J, Peng MT. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol. 1993;60:251–258. [PubMed] [Google Scholar]
  • 36.Zhang F, Dryhurst G. Oxidation chemistry of dopamine: Possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg Chem. 1993;21:392–410. doi: 10.1006/bioo.1993.1033. [DOI] [Google Scholar]
  • 37.Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 1994;17:203–209. doi: 10.1002/syn.890170310. [DOI] [PubMed] [Google Scholar]
  • 38.Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxym ethamphetamine. Brain Res. 1992;581:237–243. doi: 10.1016/0006-8993(92)90713-J. [DOI] [PubMed] [Google Scholar]
  • 39.Schinder AF, Olson EC, Spitzer NC, Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci. 1996;16:6125–6133. doi: 10.1523/JNEUROSCI.16-19-06125.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol. 1995;57:683–706. doi: 10.1146/annurev.ph.57.030195.003343. [DOI] [PubMed] [Google Scholar]
  • 41.Wang JQ, Lau YS. Dose-related alterations in nitric oxide synthase mRNA expression induced by amphetamine and the full D1 dopamine receptor agonist SKF-82958 in mouse striatum. Neurosci Lett. 2001;311:5–8. doi: 10.1016/S0304-3940(01)02128-0. [DOI] [PubMed] [Google Scholar]
  • 42.Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol. 2000;398:11–18. doi: 10.1016/S0014-2999(00)00264-8. [DOI] [PubMed] [Google Scholar]
  • 43.Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99:45–53. doi: 10.1016/S0163-7258(03)00052-4. [DOI] [PubMed] [Google Scholar]
  • 44.Stephans SE, Whittingham TS, Douglas AJ, Lust WD, Yamamoto BK. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum. J Neurochem. 1998;71:613–621. doi: 10.1046/j.1471-4159.1998.71020613.x. [DOI] [PubMed] [Google Scholar]
  • 45.Burrows KB, Nixdorf WL, Yamamoto BK. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J Pharmacol Exp Ther. 2000;292:853–860. [PubMed] [Google Scholar]
  • 46.Albers DS, Zeevalk GD, Sonsalla PK. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res. 1996;718:217–220. doi: 10.1016/0006-8993(96)00135-7. [DOI] [PubMed] [Google Scholar]
  • 47.Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci. 2004;24:11449–11456. doi: 10.1523/JNEUROSCI.3597-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Bowyer JF, Holson RR, Miller DB, O'Callaghan JP. Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation. Brain Res. 2001;919:179–183. doi: 10.1016/S0006-8993(01)03051-7. [DOI] [PubMed] [Google Scholar]
  • 49.Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 1989;243:398–400. doi: 10.1126/science.2563176. [DOI] [PubMed] [Google Scholar]
  • 50.Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther. 1995;275:1104–1114. [PubMed] [Google Scholar]
  • 51.Pu C, Vorhees CV. Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunohistochemical study. Synapse. 1995;19:97–104. doi: 10.1002/syn.890190205. [DOI] [PubMed] [Google Scholar]
  • 52.Ali SF, Newport GD, Holson RR, Slikker W, Bowyer JF. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res. 1994;658:33–38. doi: 10.1016/S0006-8993(09)90007-5. [DOI] [PubMed] [Google Scholar]
  • 53.Fuller RW, Hemrick-Luecke SK, Ornstein PL. Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist. Neuropharmacology. 1992;31:1027–1032. doi: 10.1016/0028-3908(92)90104-W. [DOI] [PubMed] [Google Scholar]
  • 54.Battaglia G, Fornai F, Busceti CL, et al. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci. 2002;22:2135–2141. doi: 10.1523/JNEUROSCI.22-06-02135.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA. Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem. 2005;92:433–441. doi: 10.1111/j.1471-4159.2004.02887.x. [DOI] [PubMed] [Google Scholar]
  • 56.Betarbet R, Greenamyre JT. Differential expression of glutamate receptors by the dopaminergic neurons of the primate striatum. Exp Neurol. 1999;159:401–408. doi: 10.1006/exnr.1999.7154. [DOI] [PubMed] [Google Scholar]
  • 57.Kiss JP, Zsilla G, Vizi ES. Inhibitory effect of nitric oxide on dopamine transporter: interneuronal communication without receptors. Neurochem Int. 2004;45:485–489. doi: 10.1016/j.neuint.2003.11.004. [DOI] [PubMed] [Google Scholar]
  • 58.Beckman JS, Beckman TW, Chen J, Parshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990;87:1620–1624. doi: 10.1073/pnas.87.4.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.O'Dell SJ, Weihmuller FB, Marshall JF. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J Neurochem. 1993;60:1792–1799. doi: 10.1111/j.1471-4159.1993.tb13405.x. [DOI] [PubMed] [Google Scholar]
  • 60.Sonsalla PK, Gibb JW, Hanson GR. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther. 1986;238:932–937. [PubMed] [Google Scholar]
  • 61.Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther. 2000;295:1077–1085. [PubMed] [Google Scholar]
  • 62.Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250:1429–1432. doi: 10.1126/science.2147780. [DOI] [PubMed] [Google Scholar]
  • 63.Le Moine C, Normand E, Block B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci USA. 1991;88:4205–4209. doi: 10.1073/pnas.88.10.4205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Di Monte DA, Royland JE, Jakowec MW, Langston JW. Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase. J Neurochem. 1996;67:2443–2450. doi: 10.1046/j.1471-4159.1996.67062443.x. [DOI] [PubMed] [Google Scholar]
  • 65.Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem. 1996;67:1770–1773. doi: 10.1046/j.1471-4159.1996.67041770.x. [DOI] [PubMed] [Google Scholar]
  • 66.Imam SZ, Newport GD, Itzhak Y, et al. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem. 2001;76:745–749. doi: 10.1046/j.1471-4159.2001.00029.x. [DOI] [PubMed] [Google Scholar]
  • 67.Fiorentini C, Gardoni F, Spano PF, Di Luca M, Missale C. Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem. 2003;278:20196–20202. doi: 10.1074/jbc.M213140200. [DOI] [PubMed] [Google Scholar]
  • 68.Cepeda C, Buchwald NA, Levine MS. Neuromodulatory actions of dopamine in the neostriatum are dependent on the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA. 1993;90:9576–9580. doi: 10.1073/pnas.90.20.9576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Xu W, Zhu JP, Angulo JA. Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse. 2005;58:110–121. doi: 10.1002/syn.20185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Broening HW, Morford LL, Vorhees CV. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse. 2005;56:84–93. doi: 10.1002/syn.20130. [DOI] [PubMed] [Google Scholar]
  • 71.Bowyer JF, Gough B, Slikker W, Lipe GW, Newport GD, Holson RR. Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. Pharmacol Biochem Behav. 1993;44:87–98. doi: 10.1016/0091-3057(93)90284-Z. [DOI] [PubMed] [Google Scholar]
  • 72.Farfel GM, Seiden LS. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J Pharmacol Exp Ther. 1995;272:868–875. [PubMed] [Google Scholar]
  • 73.Gudermann T, Numberg B, Schultz G. Receptors and G-proteins as primary components of transmembrane signal transduction. Part 1. G-protein-coupled receptors: structure and function. J Mol Med. 1995;73:51–63. doi: 10.1007/BF00270578. [DOI] [PubMed] [Google Scholar]
  • 74.Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics. 2003;13:525–534. doi: 10.1097/00008571-200309000-00001. [DOI] [PubMed] [Google Scholar]
  • 75.Reichmann H. Neuroprotection in idiopathic Parkinson's disease. J Neurol. 2002;249:21–23. doi: 10.1007/s00415-002-1304-1. [DOI] [PubMed] [Google Scholar]
  • 76.Truong JG, Rau KS, Hanson GR, Fleckenstein AE. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. Eur J Pharmacol. 2003;474:223–226. doi: 10.1016/S0014-2999(03)02080-6. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES